Diagnostics

Search documents
Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock?
ZACKS· 2025-10-17 15:21
Key Takeaways DHR is set to report Q3 2025 results on Oct. 21, with revenues estimated at $6.00 billion.Life Sciences may face softness, while Biotechnology gains from strong bioprocessing demand.Diagnostics likely grew modestly, aided by the Beckman Coulter unit and steady clinical demand.Danaher Corporation (DHR) is scheduled to release third-quarter 2025 results on Oct. 21, before market open.The Zacks Consensus Estimate for revenues is pegged at $6.00 billion, which indicates an increase of 3.4% from th ...
Why Grail Stock Soared 14% Higher on Thursday
Yahoo Finance· 2025-10-16 22:52
Key Points The cancer diagnostics specialist inked a major collaboration deal. A heavyweight Asian conglomerate will roll out its products on that continent. 10 stocks we like better than Grail › Highly specialized healthcare diagnostics company Grail (NASDAQ: GRAL) passed muster on the stock exchange on the second-to-last trading day of the week. That was on the back of news that the company has found financial backers for a push into new markets. Ultimately the stock closed the day more than 14% ...
Do You Believe in the Upside Potential of Veracyte (VCYT)
Yahoo Finance· 2025-10-16 12:06
Core Insights - Artisan Mid Cap Fund reported strong performance in Q3 2025, with returns of 8.80% for Investor Class and Advisor Class funds, and 8.83% for Institutional Class, significantly outperforming the Russell Midcap Growth Index's 2.78% return [1][2] Company Overview - Veracyte, Inc. (NASDAQ:VCYT) is a diagnostics company specializing in noninvasive cancer tests, with a market capitalization of $2.736 billion as of October 15, 2025 [2][3] - The company achieved a 14% year-over-year revenue growth, totaling $130 million, driven by strong sales of its Decipher® and Afirma® tests [3][4] Product and Market Position - Veracyte's product offerings include three approved tests: Decipher® for prostate cancer, Afirma® for thyroid cancer, and Prosigna® for breast cancer, with ongoing efforts to expand its product line [3] - The company is advancing its Percepta® Nasal Swab test for lung cancer risk assessment and plans to launch a Minimal Residual Disease platform in 2026 [3] Investment Sentiment - Interest in Veracyte among hedge funds increased, with 29 portfolios holding the stock at the end of Q2 2025, up from 24 in the previous quarter [4] - Despite the growth potential of Veracyte, some analysts suggest that certain AI stocks may offer greater upside potential with less downside risk [4]
Abbott Laboratories (NYSE:ABT) Earnings Report Overview
Financial Modeling Prep· 2025-10-15 19:00
Core Insights - Abbott Laboratories reported earnings per share (EPS) of $1.30, matching estimates, with revenue at approximately $11.37 billion, slightly below the expected $11.39 billion [1][6] Financial Performance - The company's third-quarter sales increased by 6.9%, reaching $11.37 billion, driven by strong performance in medical devices and diagnostics, despite a normalization in COVID-19 testing-related revenue [2][6] - Organic sales rose by 5.5%, or 7.5% when excluding COVID-19 testing-related revenue [2] - Abbott's operating margin was reported at 18.1% of sales, with an adjusted operating margin of 23%, marking a 40 basis point increase [3] Earnings Metrics - The GAAP diluted EPS for the quarter stood at $0.94, while the adjusted diluted EPS was $1.30, an increase from $1.21 per share reported in the same quarter last year [3][6] Management Commentary - CEO Robert Ford emphasized the company's consistent, high-quality performance, attributing it to their differentiated product pipeline [4] - Abbott has reaffirmed its full-year guidance, indicating confidence in its ongoing business strategy and market position [4] Valuation and Financial Ratios - The company's price-to-earnings (P/E) ratio is approximately 16.07, reflecting the market's valuation of its earnings [4] - Abbott's financial metrics include a debt-to-equity ratio of approximately 0.27 and a current ratio of around 1.82, suggesting a strong financial position [5] - The enterprise value to sales ratio is around 5.36, providing insight into its valuation relative to its sales [5] - Abbott's earnings yield is about 6.22%, offering a perspective on its earnings relative to its share price [5]
Abbott(ABT) - 2025 Q3 - Earnings Call Transcript
2025-10-15 14:00
Abbott Laboratories (NYSE:ABT) Q3 2025 Earnings Call October 15, 2025 09:00 AM ET Speaker0Good morning, and thank you for standing by. Welcome to Abbott's Third Quarter twenty twenty five Earnings Conference Call. All participants will be able to listen only until the question and answer portion of this call. During the question and answer session, you will be able to ask your question by pressing the star one one keys on your touch tone phone. This call is being recorded by Abbott.With the exception of any ...
Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting
Globenewswire· 2025-10-15 10:09
One year after launch of real-world CLARIFY study, preliminary data from the first 1,000 enrolled patients will be presentedLOUISVILLE, Colo., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces educational events, abstracts, and activities at the 2025 CHEST Annual Meeting, October 19-22, in Chicago, Illinois. Biodesix will be presenting data from an interim analysis of the CLARIFY study in a sponsored Learning Theater presentation. Title: Driv ...
New Strong Sell Stocks for Oct. 14th
ZACKS· 2025-10-14 11:10
Core Insights - Three stocks have been added to the Zacks Rank 5 (Strong Sell) List, indicating a negative outlook for these companies [1][2] Company Summaries - **Antero Resources (AR)**: This independent explorer is primarily engaged in the acquisition and development of natural gas, natural gas liquids, and oil resources in the Appalachian Basin. The Zacks Consensus Estimate for its current year earnings has been revised downward by approximately 25.4% over the last 60 days [1] - **BTCS Inc. (BTCS)**: Focused on blockchain infrastructure and technology, BTCS has seen its Zacks Consensus Estimate for current year earnings revised downward by nearly 23.5% over the last 60 days [2] - **Atossa Genetics (ATOS)**: A healthcare company that develops and markets cellular and molecular diagnostic risk assessment products for breast cancer. The Zacks Consensus Estimate for its current year earnings has been revised downward by 8.3% over the last 60 days [2]
Abbott Laboratories (NYSE: ABT) Q3 Earnings Preview
Financial Modeling Prep· 2025-10-14 11:00
Core Insights - Abbott Laboratories is expected to report third-quarter earnings on October 15, 2025, with an anticipated EPS of $1.30, reflecting a 7.4% increase year-over-year, and projected revenue of $11.4 billion, up from $10.63 billion a year ago [1][6] Financial Performance - The anticipated EPS of $1.30 represents an 8.3% year-over-year growth, indicating strong performance despite a recent stock decline of 0.6%, closing at $132.57 [2] - Abbott's financial metrics include a price-to-earnings (P/E) ratio of approximately 16.36 and a price-to-sales ratio of about 5.30, suggesting a favorable market valuation [4] - The company's debt-to-equity ratio stands at 0.27, indicating a relatively low level of debt, while a current ratio of 1.82 reflects strong liquidity to cover short-term liabilities [4] Strategic Focus - Abbott's strategic emphasis on expanding its diabetes care solutions is identified as a key driver for future growth, transitioning from devices to comprehensive, data-driven care solutions [3][6] - This strategic move is expected to enhance Abbott's competitive edge and contribute to its long-term success in the healthcare industry [3] Analyst Insights - The consensus earnings estimate for Abbott has been slightly adjusted downward by 0.1% over the past month, reflecting analysts' reassessment of initial projections [5] - This adjustment could influence investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock price performance [5]
ClearBridge Growth Strategy Q3 2025 Commentary (Mutual Fund:SHRAX)
Seeking Alpha· 2025-10-14 06:50
Market Overview - U.S. equities showed upward momentum in Q3, with the S&P 500 Index increasing by 8.1% and the Russell Midcap Growth Index rising by 2.8% [2] - Investor optimism was driven by favorable tariff outcomes, the passing of the One Big Beautiful Bill Act, anticipated interest rate cuts, and strong corporate earnings [2] Strategy Performance - The ClearBridge Growth Strategy outperformed its benchmark for the second consecutive quarter, supported by diversified growth contributors [3] - Key themes driving performance included artificial intelligence (AI) and cryptocurrency, with significant gains from holdings like Broadcom, AppLovin, Palantir, and Robinhood [3][4] Sector Contributions - Strong stock selection and strategic sector positioning were pivotal, with Broadcom's announcement of a new customer for its AI-focused XPU chips highlighting its market leadership [4] - L3Harris benefited from increased demand in defense spending, while TKO secured a lucrative deal with Paramount for UFC rights, showcasing the value of premium content [5] Portfolio Positioning - The strategy maintained a disciplined approach by trimming winners and reallocating capital into new opportunities, adding four new positions during the quarter [8] - Notable additions included On Holding, a premium footwear designer, and Roblox, a leading user-generated gaming platform, both expected to drive strong revenue growth [9][10] Individual Stock Performance - Leading contributors to performance included AppLovin, TE Connectivity, Broadcom, Robinhood, and L3Harris, while detractors were Vertex Pharmaceuticals, Chipotle, and HubSpot [20] - The strategy closed positions in Paylocity and Ultragenyx Pharmaceutical, reflecting a focus on evolving investment theses [20] Outlook - The strategy aims to maintain a balanced portfolio to capture upside in strong markets while providing downside protection during volatility [16] - The focus remains on monitoring stock-specific and sector allocations, reallocating capital to opportunities with attractive risk-reward profiles [17]
iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch
Globenewswire· 2025-10-13 20:05
Steven Tahmooressi to lead global marketing efforts for GraftAssure family of assays and future productsBrings 25 years of experience driving new product adoption across geographies in transplantation, oncology and immunology NASHVILLE, Tenn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it has welcomed Steven Tahmooressi to its executive leadership team as the company prepares to launch its first clinical kitted assay in 2026. As Vice P ...